$268.00
▲ +0.4% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
lean bull
▲ 4
● 21
▼ 0
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
Alnylam Initiates Mid-Stage Study of Mivelsiran in Down Syndrome-Associated Alzheimer's
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
Overview
52-week range
$283
$496
0% of range
Avg surprise (last 2)
+33.2%
Avg reaction (last 1)
-3.1%
0% positive
Latest IV / EM
59%
EM ±13.5% · $270 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Sep 30, 2025 | Sep 2025 | $1.84 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $-0.52 | $-0.58 | +10.3% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-0.44 | $1.00 | +56.0% | — | -3.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.87 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.13 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.52 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $1.15 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-2.21 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-1.40 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | BMO | $1.44 | -$0.52 | +376.9% |
Financials
Income statement (quarterly)
| Metric | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $197M | $142M | $70M | — | $82M | $67M | $55M | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $368M | $-16M | $18M | — | $-77M | $49M | $-43M | — |
| Net income | $251M | $-66M | $-57M | — | $-112M | $-17M | $-66M | — |
| EPS (diluted) | $1.84 | $-0.51 | $-0.44 | — | $-0.87 | $-0.13 | $-0.52 | — |
Balance sheet (quarterly)
| Metric | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.49B | $1.11B | $1.02B | $966M | $1.10B | $968M | $682M | $813M |
| Inventory | $75M | $72M | $66M | $79M | $76M | $84M | $94M | $89M |
| Total current assets | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | $2.98B |
| Total assets | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | $3.83B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | $4.05B |
| Total equity | $234M | $251M | $115M | $67M | $32M | $-3M | $-219M | $-221M |